Long-term continuous OGSIVEO treatment for up to 4 years was associated with further tumor size reductions, increase in ...

SpringWorks Therapeutics, Inc. announced that it expects the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) to issue an opinion on its marketing ...

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, relating to our business, operations, and financial ...

The "Desmoid Tumors Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.One of the key drivers ...

German Merck KGaA’s recently acquired subsidiary SpringWorks Therapeutics today announced that long-term efficacy and safety data from the Phase III DeFi trial of Ogsiveo (nirogacestat) were in the ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.11 per share versus the Zacks Consensus Estimate of a loss of $0.81. This compares to loss of $1.18 per share a year ago. These ...

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Small Cap Growth Fund” first quarter 2025 investor letter. A copy of the letter can be downloaded here.

SpringWorks Therapeutics (SWTX) shares rallied 9% in the last trading session to close at $44.93. This move can be attributable to notable volume with a higher number of shares being traded than in a ...

– Purchase price of $47 per share in cash represents an equity value of approximately $3.9 billion, or an enterprise value of $3.4 billion (€3.0 billion) – – Planned acquisition will immediately add ...

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) shares are trading higher on Monday after the company inked a deal to be acquired by Merck & Company, Inc. (NYSE:MRK) for $47 per share in cash. The ...